WayPoint hits a rough “patch”
This article was originally published in The Tan Sheet
FDA instructs WayPoint Biomedical Holdings to stop marketing and selling Health Essist Hangover-Free and Energy Boost Topical Patch products because the transdermal patches are unapproved drug delivery systems and the term "hangover" denotes a disease. The Huntington Beach, Calif.-based firm said June 3 it is permitted to sell the patches internationally. WayPoint added it is pursuing legal action to recover company shares issued to former President and Director Bret Hendzel, who was fired in February
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.